Related Experiment Video
Updated: Jun 20, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy
Hariprasad Trivedi1, Sumanth Daram, Aniko Szabo
1Division of Nephrology and Kidney Disease Center, Medical College of Wisconsin, Milwaukee, USA. htrivedi@mcw.edu
Insights
High-dose N-acetylcysteine significantly reduces the incidence of contrast-induced nephropathy. This meta-analysis of randomized trials confirms its preventative effect, offering a potential strategy to mitigate kidney damage from contrast agents.
Area of Science:
- Nephrology
- Pharmacology
- Radiology
Background:
- Contrast-induced nephropathy (CIN) is a significant risk following radiographic procedures.
- The prophylactic efficacy of N-acetylcysteine (NAC) for CIN remains uncertain.
- High-dose NAC administration requires further evaluation for CIN prevention.
Purpose of the Study:
- To conduct a meta-analysis evaluating the efficacy of high-dose N-acetylcysteine in preventing contrast-induced nephropathy.
- To synthesize evidence from prospective, randomized trials comparing high-dose NAC with control groups.
Main Methods:
- Meta-analysis of 16 prospective randomized trials including 1677 adult subjects.
- Inclusion criteria specified high-dose N-acetylcysteine (oral or IV) and CIN as an endpoint.
- Exclusion of trials comparing NAC with other active treatments.
Main Results:
- High-dose N-acetylcysteine demonstrated a significant reduction in CIN incidence (OR = 0.46; 95% CI, 0.33-0.63).
- Analysis included 842 subjects in the NAC arm and 835 in the control arm.
- No significant heterogeneity or publication bias was detected.
Conclusions:
- High-dose N-acetylcysteine is effective in decreasing the incidence of contrast-induced nephropathy.
- Findings support the use of high-dose NAC as a preventative measure against CIN.
- Further research may explore optimal dosing and patient populations.
Background:
Whether N-acetylcysteine is beneficial for the prevention of contrast-induced nephropathy is uncertain.
Methods:
We conducted a meta-analysis to evaluate the efficacy of high-dose N-acetylcysteine for the prevention of contrast-induced nephropathy. Our prespecified inclusion criteria were as follows: adult subjects; English language literature; administration of high-dose N-acetylcysteine a priori defined as a daily dose greater than 1200 mg or a single periprocedural dose (within 4 hours of contrast exposure) greater than 600 mg; prospective trials of individuals randomized to N-acetylcysteine, administered orally or intravenously, versus a control group; and trials that included the end point of the incidence of contrast-induced nephropathy. Trials that compared N-acetylcysteine with another active treatment were excluded.
Results:
Sixteen comparisons of patients randomized to high-dose N-acetylcysteine versus controls met our prespecified inclusion criteria with a total sample size of 1677 subjects (842 assigned to high-dose N-acetylcysteine and 835 assigned to the control arm). The average population age was 68 years, 38.7% were diabetic, and the majority was male (67.8% of reported instances). The weighted mean baseline creatinine of the overall population was 1.58 mg/dL. No significant heterogeneity was detected (P = .09; I(2) = 34%). The overall effect size assuming a common odds ratio revealed an odds ratio of 0.46 (95% confidence interval [CI], 0.33-0.63) for the occurrence of contrast-induced nephropathy with the use of high-dose N-acetylcysteine. The results of the more conservative random effects approach were similar (odds ratio = 0.52; 95% CI, 0.34-0.78). There was no evidence of publication bias (P = .34).
Conclusion:
Our results suggest that high-dose N-acetylcysteine decreases the incidence of contrast-induced nephropathy.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Imaging Studies for Cardiovascular System V: CT
Radiological Investigation I: X-ray and CT
Acute Kidney Injury I: Introduction